


Supplement TABLE 1| Cox proportional hazards regression for overall survival and cancer-specific survival before propensity score matching.


Variables	Subgroups	Overall survival				Cancer-specific survival			
		Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis	
		Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Age (year)	65-80	Ref				Ref			
	>80	1.485 (1.419-1.554)	<0.001	0.994 (0.926-1.068)	0.875	1.468 (1.402-1.538)	<0.001	0.986 (0.916-1.061)	0.702
Year of diagnosis	2004-2010	Ref				Ref			
	2011-2018	0.928 (0.893-0.965)	<0.001	1.054 (0.978-1.136)	0.171	0.929 (0.893-0.967)	<0.001	1.061 (0.982-1.146)	0.131
Sex	Female	Ref				Ref			
	Male	0.981 (0.945-1.019)	0.321			0.968 (0.931-1.006)	0.098		
Race	White	Ref				Ref			
	Black	1.154 (1.084-1.229)	<0.001	1.138 (1.068-1.214)	<0.001	1.126 (1.055-1.201)	<0.001	1.106 (1.036-1.182)	0.003
	Other	1.020 (0.958-1.085)	0.539	1.031 (0.969-1.098)	0.328	1.017 (0.954-1.084)	0.604	1.030 (0.966-1.098)	0.364
Marital status	Married	Ref				Ref			
	Unmarried	1.225 (1.179-1.272)	<0.001	1.028 (0.988-1.070)	0.166	1.224 (1.177-1.272)	<0.001	1.029 (0.988-1.072)	0.165
Primary site	Head	Ref				Ref			
	Body/tail	1.236 (1.183-1.292)	<0.001	0.987 (0.942-1.034)	0.591	1.251 (1.195-1.308)	<0.001	0.991 (0.945-1.040)	0.713

	Other	1.277 (1.210-1.347)	<0.001	0.988 (0.935-1.044)	0.667	1.301 (1.232-1.374)	<0.001	0.999 (0.944-1.057)	0.967
Histology grade	Grade I-II	Ref				Ref			
	Grade III-IV	1.366 (1.280-1.458)	<0.001	1.336 (1.252-1.427)	<0.001	1.383 (1.293-1.479)	<0.001	1.343 (1.256-1.437)	<0.001
	Unknow	2.080 (1.980-2.186)	<0.001	1.124 (1.061-1.190)	<0.001	2.148 (2.041-2.261)	<0.001	1.129 (1.065-1.198)	<0.001
Node status	Negative	Ref				Ref			
	Positive	0.873 (0.840-0.907)	<0.001	1.147 (1.100-1.195)	<0.001	0.876 (0.842-0.912)	<0.001	1.159 (1.111-1.210)	<0.001
Tumor size (cm)	<2	Ref				Ref			
	2-4	1.456 (1.358-1.561)	<0.001	1.336 (1.244-1.434)	<0.001	1.482 (1.378-1.593)	<0.001	1.345 (1.250-1.448)	<0.001
	>4	1.883 (1.753-2.024)	<0.001	1.527 (1.415-1.648)	<0.001	1.933 (1.795-2.082)	<0.001	1.536 (1.420-1.662)	<0.001
SEER stage	Localized	Ref				Ref			
	Regional	1.024 (0.959-1.095)	0.475	1.383 (1.287-1.485)	<0.001	1.045 (0.975-1.119)	0.211	1.414 (1.313-1.523)	<0.001
	Distant	2.284 (2.137-2.442)	<0.001	2.155 (2.001-2.320)	<0.001	2.386 (2.227-2.557)	<0.001	2.220 (2.057-2.397)	<0.001
Surgery	No	Ref				Ref			
	Yes	0.314 (0.299-0.330)	<0.001	0.368 (0.346-0.392)	<0.001	0.297 (0.282-0.312)	<0.001	0.348 (0.326-0.372)	<0.001
Radiation	No	Ref				Ref			
	Yes	0.577 (0.550-0.604)	<0.001	0.862 (0.819-0.908)	<0.001	0.576 (0.548-0.604)	<0.001	0.867 (0.823-0.914)	<0.001
Chemotherapy	No	Ref				Ref			
	Yes	0.492 (0.473-0.512)	<0.001	0.456 (0.436-0.476)	<0.001	0.493 (0.474-0.513)	<0.001	0.450 (0.431-0.471)	<0.001

Supplementary Figure 1. Patient selection



Supplementary Figure 2 Subgroup analysis of RT or non-RT for OS in elderly patients with PDAC before PSM



Supplementary Figure 3 Subgroup analysis of RT or non-RT for CSS in elderly patients with PDAC before PSM

